Antibiotics are wonderful drugs for treating bacterial infections. Unfortunately, disease-causing bacteria can become resistant to antibiotics that are meant to kill them. This is called selective pressure – the bacteria that are susceptible to the drug are killed, but the ones that withstand the antibiotic survive and proliferate. This process results in the emergence of antibiotic-resistant strains.
Once a bacterial strain is resistant to several different antibiotics, it has become a multi-drug-resistant (MDR) microbe. When there are virtually no antibiotics available to treat an infected patient, a microbe is said to be “pan-resistant.“ These strains are becoming more and more common in hospitals and in the community at large. You might have heard of some of them: for instance, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and carbapenem-resistant Enterobacteriaceae (CRE).
Bacteria can become drug-resistant in two ways – resistance can be natural, meaning that the genes conferring resistance are already present in the bacterial chromosome, or they can be acquired through mutation or by picking up antibiotic-resistance genes from other microbes.
It is now possible to use new DNA-sequencing technologies to take a closer look at how the antibiotic resistance can make some bacteria weaker or stronger. And in a new study, we found that – contrary to conventional wisdom around antibiotics – resistance can actually make some bacteria fitter and even more virulent.
Is fitness always a cost of antibiotic resistance?
For decades, an established dogma in the field of infectious diseases has been the so-called “fitness cost of antibiotic resistance.“ We believed there was a trade-off for bacteria between antibiotic resistance and how well they could carry out their regular tasks of living.
The idea is that while antibiotic-resistant strains cause infections that are more difficult to treat, they are also less hardy. Either they are less able to survive within an infected host and/or they’re less virulent, causing less severe infection, with a reduced ability to be passed along to another human.
And we know that this picture is true for some bacteria. Both Mycobacterium tuberculosis (which causes tuberculosis) and Mycobacterium leprae (which causes leprosy) can become resistant to the drug rifampicin, which is one of the main antibiotics used to treat these diseases.
For M. tuberculosis and M. leprae, resistance to rifampicin comes thanks to a mutation in one gene. The mutation buys the bacteria the ability to fend off antibiotics, but it interferes with their normal cell physiology and the factors that make them virulent. As we’d expect, resistance comes with a clear fitness cost in this case.
But what if resistance actually makes some bacteria stronger and deadlier? Our team used DNA sequencing techniques to tease apart the relationship between antibiotic resistance and fitness cost in infections in laboratory animals. It turns out that for some bacteria, drug resistance actually makes them fitter.
Using ‘jumping genes’ to compare resistance and fitness
We analyzed a bacterium called Pseudomonas aeruginosa. It’s a major cause of infections in people with cystic fibrosis, as well as very ill patients in intensive care units (ICU) and people with weakened immune systems.
P. aeruginosa is naturally resistant to several antibiotics and can acquire resistance to numerous others to become multi-drug-resistant or even pan-resistant.
To find out if there was a fitness cost from resistance, we created mutant strains of P. aeruginosa using “jumping genes” to insert mutations into the bacteria. Because we wanted to see what the cost of resistance was, we made two kinds of mutant strains. Some mutant strains lost their natural-resistance genes, while other mutant strains acquired resistance due to inactivation of genes that made them susceptible to antibiotics.
This meant that we could use DNA sequencing to determine how loss of each mutated gene affected the overall ability of P. aeruginosa to cause an infection in mice and the bacterium’s overall fitness.
Antibiotic resistance doesn’t always come at a cost
With an organism like P. aeruginosa, physicians often turn to a class of antibiotics called carbapenems to treat infections. Carbapenems kill P. aeruginosa through a channel or pore in the bacteria’s outer wall made by the protein OprD. That pore lets carbapenems in, which kills the cell. In more than 70% of human infections with carbapenem-resistant strains of P. aeruginosa, the bacterium has stopped making the OprD pore – meaning the killer antibiotic now cannot get inside the cell. We created mutant strains of P. aeruginosa that could not produce the OprD protein, giving them an acquired resistance to carbapenems.
In our experiments, it turns out the fitness is not a trade-off for resistance in P. aeruginosa. We found that the most fit mutants were those that had become carbapenem-resistant because the OprD protein was no longer made.
In mice with P. aeruginosa infections in their gastrointestinal tracts, the OprD mutants initially represented less than 0.1% of the strains used to establish infections. But after five days, the OprD mutants comprised more than 40% of the strains we recovered from the mice’s GI tracts. The “mutant” bacteria didn’t just spread because they were hard to kill (we did not give any antibiotics to the mice) but because they were fitter than the other bacterial strains infecting the mice.
We saw something similar when we used the mutant strains to give the mice bacterial pneumonia. The OprD mutants once again emerged as the predominant strains, but many of them were also resistant to another common antibiotic called fosfomycin. Like carbapenem resistance, fosfomycin resistance is also due to a single gene.
Overall, when bacteria acquired resistance to fosfomycin and carbapenem antibiotics, they became fitter and more virulent. This counters the more commonly accepted concept that there is a fitness cost due to antibiotic resistance.
In fact, we found that the mutant strains that lost their natural antibiotic resistance became less fit. So acquiring resistance made the bacterial cells stronger, while losing resistance made them weaker.
What about other kinds of bacteria?
To see if this effect was limited to P. aerginoa, we decided to look at two other bacterial species to see if antibiotic resistance made them fitter as well.
We looked at another multidrug and even pan-drug antibiotic resistance organism called Acinetobacter baumannii, which causes many types of severe infections in the lungs, blood and skin, and a non-drug-resistant bacterium, Vibrio cholerae, which causes cholera. V. cholera also has some natural antibiotic resistance genes.
Along with coauthors Drs John Mekalanos and Stephen Lory at Harvard Medical School, we found that for A. baumannii and V. cholerae, the loss of antibiotic resistance was associated with loss of fitness and a weakened ability to cause infection.
But, when the bacteria acquired antibiotic resistance through a genetic mutation, they became more virulent, and had a stronger ability to cause infections in preclinical laboratory models of infections.
What does this mean for strategies to combat antibiotic resistant bacteria?
We do not expect these findings to be true for every kind of bacteria. But even if they apply to just some organisms, it means that resistant strains will not go away if we simply reduce or control antibiotic use.
There is a general belief that if antibiotics are used only when needed, the antibiotic-susceptible strains will outcompete the less fit – but resistant – strains. But this strategy might not be enough to combat bacteria that get stronger when they become drug-resistant instead of weaker.
Handwashing and related measures can control the spread of resistant bacteria. But we also need vaccines and premade antibodies that can be given to people who are at risk for, or actually infected with, drug-resistant microbes.
That is something our research team from Harvard Medical School and Brigham and Women’s Hospital is pursuing. We are investigating the development of a potentially very broad-spectrum vaccine along with another product, a human antibody, that could provide immunity to most drug-resistant bacteria, including tuberculosis and the feared MRSA strains, and perhaps even organisms causing diseases such as malaria.
Gerald Pier is an inventor of intellectual properties (human monoclonal antibody to PNAG and PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC, entities in which GBP also holds equity. As an inventor of intellectual properties, GBP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC. GBP’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies.. He receives funding from the NIH and Morris Animal Foundation for development of PNAG-based vaccines and therapies.
David Skurnik is inventor of intellectual properties (use of human monoclonal antibody to PNAG and use of PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC. As inventor of intellectual properties, he has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC
Authors: The Conversation